The Pollen Allergy drugs in development market research report provides comprehensive information on the therapeutics under development for Pollen Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Pollen Allergy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Pollen Allergy - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Pollen Allergy and features dormant and discontinued products.

GlobalData tracks 25 drugs in development for Pollen Allergy by 14 companies/universities/institutes. The top development phase for Pollen Allergy is phase ii with ten drugs in that stage. The Pollen Allergy pipeline has 24 drugs in development by companies and one by universities/ institutes. Some of the companies in the Pollen Allergy pipeline products market are: Allergy Therapeutics, Worg Pharmaceuticals Hangzhou and Roxall Medizin.

The key targets in the Pollen Allergy pipeline products market include Interleukin 4 Receptor Subunit Alpha (CD124 or IL4R), Pituitary Adenylate Cyclase Activating Polypeptide (ADCYAP1), and Pollen Allergen Bet v 1.

The key mechanisms of action in the Pollen Allergy pipeline product include Interleukin 4 Receptor Subunit Alpha (CD124 or IL4R) Antagonist with one drug in Phase II. The Pollen Allergy pipeline products include five routes of administration with the top ROA being Subcutaneous and eight key molecule types in the Pollen Allergy pipeline products market including Allergenics (Allergen), and Monoclonal Antibody.

Pollen Allergy overview

Pollen allergy, characterized by sensitivity to the minute particles released seasonally by trees, grasses, and weeds, occurs when these pollen grains disperse through the air in their journey to fertilize plants. The particles frequently infiltrate noses, eyes, ears, and mouths, instigating the onset of allergy symptoms. Sneezing, nasal congestion, and itchy eyes are common manifestations of the immune system’s response to these airborne allergens, impacting individuals susceptible to pollen-induced allergies.

For a complete picture of Pollen Allergy’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.